Teriparatide Dosage Guide

Complete guide to Teriparatide dosing protocols, administration methods, and safety considerations for research purposes.

Research Use Only: The dosage information provided is for educational and research purposes. Peptides are not approved by the FDA for human use. Always consult with a healthcare professional.

Recommended Dosage

20mcg subcutaneously once daily. Maximum treatment duration of 2 years due to theoretical osteosarcoma risk from rat studies.

Administration Method

Subcutaneous injection in thigh or abdomen once daily. Delivered via multi-dose pen. Should sit or lie down after injection due to orthostatic hypotension risk.

Side Effects to Monitor

Orthostatic hypotension, leg cramps, nausea, dizziness, headache, and injection site reactions. Transient hypercalcemia possible.

Safety Considerations & Risks

Boxed warning for osteosarcoma risk (seen in rat studies at high doses). Contraindicated in Paget's disease, unexplained elevated ALP, prior bone radiation, or bone metastases.